Keyphrases
AIDS/HIV
100%
Pharmacokinetics
63%
Infected children
52%
Human Immunodeficiency Virus Type 1 (HIV-1)
44%
HIV-infected children
41%
Ritonavir
30%
Meningitis
29%
Haemophilus Influenzae Type b
29%
Antiretroviral Therapy
27%
Ceftriaxone
27%
Pediatric Patients
26%
Infections in children
26%
Penicillin
25%
Haemophilus Influenzae
24%
United States
24%
Highly Active Antiretroviral Therapy (HAART)
24%
Pediatric
23%
Human Immunodeficiency Virus Infection
23%
Protease Inhibitors
20%
HIV Patients
20%
Respiratory Syncytial Virus
19%
Zidovudine
18%
Placebo
16%
Antibiotics
16%
Immunogenicity
16%
Bacteremia
16%
Streptococcus Pneumoniae
15%
Nevirapine
15%
Cerebrospinal Fluid
15%
Combined Antiretroviral Therapy (cART)
14%
Ampicillin
13%
Lopinavir
13%
AIDS Clinical Trials
13%
Older Adults
12%
Stavudine
12%
Pediatric AIDS
12%
Viral Load
12%
Invasive Pneumococcal Disease
12%
Vaccination
12%
Perinatally HIV-infected
12%
Non-susceptible
12%
Perinatally Acquired HIV
11%
Lamivudine
11%
Ampicillin Resistance
11%
Antiretroviral
11%
Disease Severity
11%
Young children
11%
Rifampin
11%
Preadolescent children
10%
S. Pneumoniae
10%
Pharmacology, Toxicology and Pharmaceutical Science
HIV
98%
Pharmacokinetics
81%
Infection
52%
Penicillin Derivative
25%
Meningitis
24%
Ceftriaxone
23%
Disease
23%
Human Immunodeficiency Virus Infection
21%
Ritonavir
20%
Clinical Trial
15%
Human Immunodeficiency Virus 1
15%
Stavudine
15%
Pneumococcal Infection
14%
Proteinase Inhibitor
14%
Bloodstream Infection
13%
Zidovudine
13%
Haemophilus Influenzae Type B
12%
Rifampicin
12%
Nevirapine
12%
Streptococcus
12%
Antibiotics
11%
Adverse Event
11%
Immunogenicity
10%
Amikacin
10%
Lopinavir Plus Ritonavir
10%
Placebo
10%
Didanosine
9%
Ampicillin
9%
Chloramphenicol
9%
Combination Therapy
9%
Haemophilus influenzae
8%
Tolerability
8%
Bacterial Meningitis
8%
Linezolid
8%
Sepsis
7%
Lamivudine
7%
Bacterial Infection
7%
Clindamycin
7%
Pneumococcus Vaccine
7%
Cotrimoxazole
6%
Haemophilus Meningitis
6%
Streptococcus Group A
6%
Shunt Infection
6%
Darunavir Plus Ritonavir
6%
Aminoglycoside
6%
Antiinfective Agent
6%
Live Attenuated Influenza Vaccine
6%
Measles Mumps Rubella Vaccine
6%
Chickenpox Vaccine
6%
Human Respiratory Syncytial Virus
6%
Medicine and Dentistry
Human Immunodeficiency Virus
50%
Pediatrics
31%
Diseases
29%
Infection
26%
Antiretroviral Therapy
17%
Pneumococcus
12%
Human Immunodeficiency Virus Infection
12%
Adolescence
11%
Clinical Trial
10%
Pneumococcal Infection
10%
Penicillin Derivative
9%
Serotype
8%
Shunt Infection
8%
Neonatal Infant
8%
Pathogen
7%
Human Immunodeficiency Virus 1
6%
Bloodstream Infection
6%
Combination Therapy
6%
Pediatrics Patient
6%
Bacterial Meningitis
6%
Ritonavir
6%
Sepsis
6%
Haemophilus Influenzae Type B
5%
Proteinase Inhibitor
5%
Antibiotics
5%
Brain Ventricle Peritoneum Shunt
5%
Meningitis
5%
Cerebrospinal Fluid Shunting
5%
Cytotoxic T-Cell
5%
HIV/AIDS
5%
Toddlers
5%
Gestational Age
5%
Pneumococcus Vaccine
5%